CTOs on the Move

Centre for Commercialization of Regenerative Med

www.ccrm.ca

 
Centre for Commercialization of Regenerative Medicine , a Canadian not-for-profit organization funded by the Government of Canada`s Networks of Centres of Excellence program, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. CCRM aims to accelerate the translation of scientific discovery into marketable products for patients with specialized teams funding, and infrastructure. CCRM sources and evaluates intellectual property from around the globe, offers various consulting services, conducts development projects with partners, and establishes new companies built around strategic bundles of ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ccrm.ca
  • The Banting Institute Suite 110-100 College Street
    Toronto, ON CAN M5G 1L5
  • Phone: 416.978.3751

Executives

Name Title Contact Details
Kim Warren
Chief Technology Officer Profile

Similar Companies

Seven Bridges

Personalized medicine, drug discovery, diagnostic testing, and foundational genomic research all start with bioinformatics. The world`s largest research institutions use Seven Bridges` software platform to help them analyze, store, and act on genomic and other biological data.

Xcellerex

Xcellerex is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Codiak Biosciences

Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth. Recent discoveries have transformed our understanding of the role of exosomes in the body. We now know that these natural, cell-derived vesicles can act as a potent and safe delivery system for multiple therapeutic payloads. Recognizing the enormous potential of exosomes, Codiak is applying leading-edge translational science and rigorous drug development to build a pipeline of candidates with broad utility and the capacity to address currently “undruggable” targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy and other therapy areas. At Codiak, we are working to create a major shift in the development of tomorrow`s medicines through scientific ambition, remarkable ingenuity and deep passion for improving patients` lives. Located in the heart of Boston`s biotechnology hub in Cambridge, Massachusetts, we are advancing a bold vision by tapping into the unique talents of a varied pool of individuals who together are achieving truly exceptional work.

BH1 (Better Health for Everyone)

BH1 (Better Health for Everyone) is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Access BIO

Access BIO is a Boyce, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.